Viral Hepatitis

You have full text access to this OnlineOpen article

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B^†

Hyun Woong Lee^1,2,3,
Heon Ju Lee^3,4,
Jae Seok Hwang^3,5,
Joo Hyun Sohn^3,6,
Jae Young Jang⁷,
Ki Jun Han⁸,
Jun Yong Park^1,3,9,
Do Young Kim^1,3,9,
Sang Hoon Ahn^1,3,9,
Yong Han Paik^1,3,9,
Chun Kyon Lee^3,10,
Kwan Sik Lee^1,3,9,
Chae Yoon Chon^1,3,9,
Kwang-Hyub Han^1,3,9,‡,*

Article first published online: 9 NOV 2009

DOI: 10.1002/hep.23323

Issue

Hepatology

Volume 51, Issue 2, pages 415–421, February 2010

Additional Information

How to Cite

Lee, H. W., Lee, H. J., Hwang, J. S., Sohn, J. H., Jang, J. Y., Han, K. J., Park, J. Y., Kim, D. Y., Ahn, S. H., Paik, Y. H., Lee, C. K., Lee, K. S., Chon, C. Y. and Han, K.-H. (2010), Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology, 51: 415–421. doi: 10.1002/hep.23323

Author Information

¹
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
²
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
³
Liver Cirrhosis Clinical Research Center, Seoul, Korea
⁴
Department of Internal Medicine, Yeungnam University College of Medicine, Seoul, Korea
⁵
Department of Internal Medicine, Keimyung University School of Medicine, Seoul, Korea
⁶
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
⁷
Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea
⁸
Department of Internal Medicine, Kwandong University College of Medicine, Seoul, Korea
⁹
Department of Internal Medicine, Yonsei Institute of Gastroenterology, Seoul, Korea
¹⁰
Department of Internal Medicine, National Health Institute Corporation Ilsan Hospital, Seoul, Korea

^‡
fax: 82-2-312-7833.

Email: Kwang-Hyub Han (gihankhys@yuhs.ac)

^*Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaimun-gu, Seoul 120-752, Korea

^†
Potential conflict of interest: Nothing to report.
^‡
fax: 82-2-312-7833.

Publication History

Issue published online: 25 JAN 2010
Article first published online: 9 NOV 2009
Manuscript Accepted: 10 SEP 2009
Manuscript Received: 30 JAN 2009

Funded by

Good Health R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea. Grant Number: A050021

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (283K)

References

1
Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.
2
Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283–290.
3
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.
4
Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. HEPATOLOGY 2001; 34: 139–145.
Direct Link:
5
Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998–1002.
6
Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996; 48: 8–16.
Direct Link:
7
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–1263.
8
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61–68.
9
Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562–568.
10
Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. HEPATOLOGY 1998; 27: 1670–1677.
Direct Link:
11
Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. HEPATOLOGY 2001; 33: 751–757.
Direct Link:
12
Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276–1282.
Direct Link:
13
Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714–1722.
14
van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420–424.
15
Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. HEPATOLOGY 2000; 32: 803–806.
Direct Link:
16
Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005; 48: 341–349.
17
Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: 208–212.
Direct Link:
18
Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39: 614–619.
19
Lee HC, Suh DJ, Ryu SH, Kim H, Shin JW, Lim YS, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003; 52: 1779–1783.
20
Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. HEPATOLOGY 2003; 38: 1267–1273.
Direct Link:
21
Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY. 2007; 45: 507–539.
Direct Link:
22
Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. HEPATOLOGY 1999; 30: 1082–1087.
Direct Link:
23
Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172–180.
24
Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001; 33: 1527–1532.
Direct Link:
25
Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.
26
Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348: 808–816.
27
Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. HEPATOLOGY 2003; 37: 748–755.
Direct Link:

View Full Article with Supporting Information (HTML) Get PDF (283K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B^†

Hepatology

How to Cite

Author Information

Publication History

Funded by

ARTICLE TOOLS

References

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B†

Hepatology

How to Cite

Author Information

Publication History

Funded by

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

References

More content like this

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B^†